Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman & Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Mary Kate - Citi Roger Song - Jefferies Eva Fortea-Verdejo - Wells Fargo Anupam Rama - JPMorgan David Nierengarten - Wedbush Operator Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals First Quarter 2025 Earnings Conference Call.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share.
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know
The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Big Pipeline Updates From Kiniksa Pharmaceuticals
Big Pipeline Updates From Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.06.
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Liisa Bayko - Evercore ISI Paul Choi - Goldman Sachs Eva Fortea-Verdejo - Wells Fargo David Nierengarten - Wedbush Securities Anupam Rama - JPMorgan Operator Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call.
